Cytokinetics Inc (CYTK) Peer Comparison

$61.23

$-1.10 (-1.76%)

As on 23-Oct-2026 16:00EDT

Market cap

$8,512 Mln

Revenue (TTM)

$71 Mln

P/E Ratio

--

P/B Ratio

60.3

Div. Yield

0 %

Edit

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	8,512	18,719	15,989	16,015	14,259
Revenue ($ Mln)	71	2,838	2,436	1,054	1,664
Net Profit ($ Mln)	-894.00	517.83	860.62	755.85	413.60
Net Margin (%)	-1,259.87	18.24	35.33	71.69	24.86
RoE (%)	--	87.53	42.98	--	430.03
Price to Earnings	--	37.16	20.36	18.65	36.73
Price-To-Book	60.31	39.67	7.82	9.82	25.20

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Operating Revenue	70.96	2,838.39	2,435.92	1,054.37	1,663.74
Cost of Revenue	10.66	2,011.22	85.67	103.47	292.42
Gross Profit	77.91	760.62	2,236.43	588.53	1,167.84
Operating Expenses	764.92	220.03	1,378.74	841.45	440.53
Operating Profit (EBIT)	-704.62	607.14	971.51	109.45	930.79
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-894.00	626.99	1,035.47	101.11	583.34
Provision for Tax	0.00	109.17	174.84	-654.74	169.74
Profit after Tax (Net Income)	-894.00	517.83	860.62	755.85	413.60
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Shareholder's Funds	-173.49	584.94	1,843.76	1,435.90	143.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	1,916.61	221.56	288.55	384.48	2,089.43
Current Liabilities	181.43	1,496.10	361.93	464.70	344.44
Total Liabilities	1,424.54	1,975.47	2,844.42	1,302.02	2,525.32

Assets ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Non-Current Assets	716.06	1,057.60	1,243.41	895.24	1,644.38
Current Assets	1,208.49	1,245.00	1,250.82	1,389.84	933.02
Total Assets	1,424.54	1,975.47	2,844.42	1,302.02	2,525.32
Total Debt*	1,270.56	146.04	165.93	449.89	2,146.65
Net Current Assets	1,027.06	0.00	888.90	925.52	588.59

Cashflow ($ Mln)

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-510.01	713.22	884.27	51.77	651.56
Cash Flow from Investing Activities	16.67	-31.14	350.44	-8.15	-545.81
Cash from Financing Activities	524.46	-860.39	-969.59	34.89	-85.17
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
ROCE (%)	-122.85	57.43	32.82	-30.01	15.61
ROE (%)	197.47	87.53	42.98	163.18	430.03
ROA (%)	-51.64	15.73	29.32	31.68	16.19
EBIT Margin (%)	-1,175.80	21.70	41.82	5.73	36.28
Net Margin (%)	-1,259.87	18.24	35.33	71.69	24.86
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Revenue Growth (%)	-17.24	20.35	9.23	114.85	41.15
EBIT Growth (%)	-62.26	18.61	29.37	136.39	-14.99
Net Profit Growth (%)	-47.45	19.59	42.89	378.76	-25.78
EPS Growth (%)	-41.03	28.06	50.42	353.27	-23.48
Book Value Growth (%)	57.45	108.60	-0.70	816.12	-55.81

Valuation Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Price / Earnings	-9.91	36.06	15.79	-59.76	24.99
Price / Book Value	60.31	39.67	7.82	9.82	25.20
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-10.85	28.53	14.43	208.25	22.63
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debt to Equity	-6.45	0.00	0.00	0.27	13.50
Short term debt to equity ratio	-0.28	0.00	0.00	0.05	1.46
Current Ratio	6.66	0.83	3.46	2.99	2.71
Quick Ratio	6.66	0.83	3.38	2.32	2.31
Interest Coverage	-6.16	--	--	1.62	29.73

Operating Efficiency Ratios

	Cytokinetics Inc (CYTK)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Ascendis Pharma A/S - ADR	Halozyme Therapeutics (HALO)
Debtors to sales (%)	34.43	15.77	13.74	21.25	27.40
Asset Turnover	0.04	0.86	0.83	0.44	0.65
Receivable days	71.39	50.42	43.48	85.52	98.04
Inventory Days	--	--	96.17	1,056.70	254.12
Payable days	770.29	6.26	147.97	331.01	24.86
Cash Conversion Cycle	--	--	-8.32	811.21	327.29

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly